Speciality European Pharma was founded in 2006 to acquire, develop, register and commercialise speciality therapeutic products for the expanding European market.
Taking the lead in urology
Our mission is to be recognised as the leading urologist focused specialty pharmaceutical business in Europe, marketing products directly in the leading EU markets and through expert partners in other regions and countries.
We are dedicated to improving the range of products available in Europe to treat urological diseases, including the urological cancers.
The prevalence of many urological conditions is increasing, largely as a result of the ageing population, and many of these represent major, unmet clinical needs.
Treating prostate cancer
Our lead product is Plenaxis® (abarelix). Plenaxis is a novel product – it is the first in a new class of hormonal products (the GnRH blockers) and it is used to treat advanced and metastatic prostate cancer. Plenaxis has been launched in Germany and, having been approved in 11 further EU countries, is now scheduled for pan European roll out during 2011 and beyond.
A team with a strong track record
Our team is highly experienced and has a track record of success in bringing new products from the late stages of development, through the European regulatory processes, on to the market. Speciality European Pharma has already demonstrated an ability to identify and acquire attractive, late stage products.
In the UK, France, Germany and Italy
Speciality European Pharma has its own commercial operations in the large European markets – the UK, France, Germany and Italy. In other countries, we will partner with local companies with established commercial operations.
Do you have what it takes to join Speciality European Pharma? Click here for more information.